North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032
Overview
The North America Pharmacogenetics Testing in Psychiatry-Depression Market is expected to reach a 2,060.30 USD Billion by 2032 and is projected to grow at a CAGR of 12.87% from 2025 to 2032.
Revenue, 2024 (USD Billion)
981.28
Forecast, 2032 (USD Billion)
2,060.30
CAGR, 2024 - 2032
12.87%
Report Coverage
North America
North America Pharmacogenetics Testing in Psychiatry-Depression Market 2018-2032 USD Billion
North America Pharmacogenetics Testing in Psychiatry-Depression Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 981.28 USD Billion
- Projected Market Size (2032): 2,060.30 USD Billion
- CAGR (2025-2032): 12.87%
Key Findings of North America Pharmacogenetics Testing in Psychiatry-Depression Market
- The North America Pharmacogenetics Testing in Psychiatry-Depression Market was valued at 981.28 USD Billion in 2024.
- The North America Pharmacogenetics Testing in Psychiatry-Depression Market is likely to grow at a CAGR of 12.87% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Whole Genome Sequencing in Test Segment accounted for the largest share of the market with a revenue of 1,047.42 USD Billion
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 17.08% during the forecast period from 2024 to 2032.
North America Pharmacogenetics Testing in Psychiatry-Depression Market Scope
North America Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
Product
- Software and Services
- Instruments
- Consumables
Test
- Chromosomal Array Based Tests
- Whole Genome Sequencing
Type
- Psychotic Disorders
- Eating Disorders
- Bipolar Disorders
- Mood Disorders
- Depression
- Anxiety
Gene
- COMT
- MTHFR
- SLC6A4
- CYP3A4
- HLA-A
- HTR2A/C
- Others
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
Patient
- Child
- Geriatric
- Adult
Distribution Channel
- Others
- Hospital Pharmacy
- Third Party Distribution
- Direct Tender
End User
- Others
- Hospital and Clinics
- Diagnostics Laboratories
- Academic And Research Institutes
North America Pharmacogenetics Testing in Psychiatry-Depression Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 981.28 USD Billion |
| Market Value in 2032 | 2,060.30 USD Billion |
| CAGR (2025-2032) | 12.87% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Product,Test,Type, Gene,Patient,Distribution Channel,End User |
Regional Insights:
-
Leading Market (2024-2032): North America, leading in terms of revenue 981.28 USD Billion in 2024
- Key Country: U.S., leading in terms of revenue with value of 807.70 USD Billion in 2024.
Segments and Scope
-
North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Product
- Consumables is the largest segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 500.99 USD Billion in the year 2024.
- Consumables is the Fastest growing segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 14.67 % in forecast period 2025-2032.
-
North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Test
- Whole Genome Sequencing is the largest segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 1,047.42 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 15.70 % in forecast period 2025-2032.
-
North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Type
- Anxiety is the largest segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 405.01 USD Billion in the year 2024.
- Anxiety is the Fastest growing segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 15.36 % in forecast period 2025-2032.
-
North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Gene
- CYP2C19 is the largest segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 280.48 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 17.08 % in forecast period 2025-2032.
-
North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Patient
- Adult is the largest segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 588.11 USD Billion in the year 2024.
- Adult is the Fastest growing segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 14.03 % in forecast period 2025-2032.
-
North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 484.00 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 14.10 % in forecast period 2025-2032.
-
North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By End User
- Hospital and Clinics is the largest segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 475.29 USD Billion in the year 2024.
- Hospital and Clinics is the Fastest growing segment in North America Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 14.31 % in forecast period 2025-2032.
North America Pharmacogenetics Testing in Psychiatry-Depression Market Company Share Analysis
| Company Name |
|
||
| Myriad Genetics, Inc. | |||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| Qiagen | |||
| Sonic Healthcare Limited | |||
North America Pharmacogenetics Testing in Psychiatry-Depression Market Geographical Sales Distribution, 2018-2032 USD Billion
North America Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The North America Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Product,Test,Type, Gene,Patient,Distribution Channel,End User.
North America Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 981.28(Revenue in USD Billion) in 2022.
North America Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 12.87% during the forecast period of 2024 to 2032.
The Whole Genome Sequencing segment is expected to dominate the North America Pharmacogenetics Testing in Psychiatry-Depression Market, holding a largest market share of 1,047.42 USD Billion in 2024
Coming Soon....
North America Pharmacogenetics Testing in Psychiatry-Depression Market Scope
North America Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
Product
- Software and Services
- Instruments
- Consumables
Test
- Chromosomal Array Based Tests
- Whole Genome Sequencing
Type
- Psychotic Disorders
- Eating Disorders
- Bipolar Disorders
- Mood Disorders
- Depression
- Anxiety
Gene
- COMT
- MTHFR
- SLC6A4
- CYP3A4
- HLA-A
- HTR2A/C
- Others
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
Patient
- Child
- Geriatric
- Adult
Distribution Channel
- Others
- Hospital Pharmacy
- Third Party Distribution
- Direct Tender
End User
- Others
- Hospital and Clinics
- Diagnostics Laboratories
- Academic And Research Institutes
Frequently Asked Questions
The North America Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Product,Test,Type, Gene,Patient,Distribution Channel,End User.
North America Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 981.28(Revenue in USD Billion) in 2022.
North America Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 12.87% during the forecast period of 2024 to 2032.
The estimated market value of the North America Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 2,060.30 (USD Billion).
North America Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Frequently Asked Questions
The North America Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Product,Test,Type, Gene,Patient,Distribution Channel,End User.
North America Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 981.28(Revenue in USD Billion) in 2022.
North America Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 12.87% during the forecast period of 2024 to 2032.
The estimated market value of the North America Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 2,060.30 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.